Veracyte Stock Forecast
NASDAQ: VCYTHealth CareMedical SpecialitiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
VCYT analyst consensus
Consensus (13 analysts)
buy
Avg. price target
$58.42+29.16%
- Strong buy 2
- Buy 9
- Hold 1
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 13 Wall Street analysts covering Veracyte (2026-10-07), 11 rate the stock a buy or strong buy, 1 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $58.42, with a high estimate of $70.00 and a low estimate of $44.00. The average target implies upside of 29.2% from the current price of $45.23.
The spread between the highest and lowest targets is 59.1%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for VCYT.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 15% |
| Buy | 9 | 69% |
| Hold | 1 | 8% |
| Sell | 1 | 8% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $44.00 | -2.72% |
| Average target | $58.42 | +29.16% |
| High target | $70.00 | +54.76% |